Skip to main content

Table 3 Costs, QALY and net monetary benefit results from 10-year time horizon scenario

From: Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis

 

Combination therapy

5-ARI

α-blockers

FT

Price $11,000

Price $4500

Costs per patient ($)

1453.10

1558.71

1571.75

12,043.58

5570.97

QALY per patient

4.20

4.20

4.20

4.27

4.28

Willingness-to-pay threshold at $150,000

     

Net Monetary Benefit (NMB) ($)

628,546.90

628,441.29

628,428.25

628,456.42

636,429.03

Willingness-to-pay threshold at $50,000

     

Net Monetary Benefit (NMB) ($)

208,546.90

208,441.29

208,428.25

201,456.42

208,429.03

  1. QALY quality-adjusted life years, 5-ARI 5-α-Reductase inhibitors, FT Fexapotide triflutate